This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Covidien (NYSE: COV), a leading global provider of healthcare products, announced the expansion of its portfolio of radiofrequency ablation (RFA) catheters with the launch of the Barrx™ Channel RFA Endoscopic Catheter for treating Barrett’s esophagus and certain gastrointestinal bleeding disorders
1. Left untreated, Barrett’s esophagus, a precancerous condition of the esophageal lining, can lead to life-threatening cancer of the esophagus.
The Barrx line of RFA catheters is based on Covidien’s proprietary technology that carefully controls the amount of RF energy delivered to remove diseased tissue, thereby allowing the growth of healthy tissue. Endoscopic surgeons and gastroenterologists can shorten procedure time with the new Channel RFA device, as this patient-centric design allows for fewer endoscope introductions and removals (compared to other Barrx catheters). The innovative technology in the Channel catheter enables a 7.5mm wide electrode to easily pass through a 2.8mm diameter endoscope working channel.
“Covidien continues to offer patients and physicians a solution to address Barrett’s esophagus,” said Vafa Jamali, Vice President and General Manager, GI Solutions, Covidien. “The newest addition to the Barrx portfolio is designed to simplify the procedure by delivering our proven RF technology through the working channel of the endoscope.”
Other features and benefits of the new device include a transparent ablation electrode for enhanced visualization and a unique rotatable shaft design that provides additional control and maneuverability. The Barrx Channel RFA Endoscopic Catheter is available in the United States and Europe.
For more information about Covidien’s Barrx solutions, RFA eradication therapy and Barrett’s esophagus, please visit
Covidien is a leading global healthcare products company that creates innovative medical solutions for better patient outcomes and delivers value through clinical leadership and excellence. Covidien manufactures, distributes and services a diverse range of industry-leading products in medical devices and supplies. With 2012 revenue of $9.9 billion, Covidien has 38,000 employees worldwide in 70 countries, and its products are sold in over 140 countries. Please visit
www.covidien.com to learn more about our business.
1 The Barrx Channel RFA Endoscopic Catheter (used with the Barrx™ Flex RFA Energy Generator) is indicated for use in the coagulation of bleeding and non-bleeding sites in the gastrointestinal tract, including, but not limited to, the esophagus. Indications include esophageal ulcers, Mallory-Weiss tears, arteriovenous malformations, angiomata, Barrett’s esophagus, Dieulafoy lesions, angiodysplasia, Gastric antral vascular ectasia (GAVE) and radiation proctitis (RP).